Cohort Study: Among patients with resolved Hepatitis B infections and concomitant autoimmune disease, exposure to prednisone doses greater than 20 mg/day were associated with a high risk for HBV reactivation or hepatitis flare.
21 Jan, 2022 | 09:39h | UTCAverage corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection – Annals of Rheumatic Disease (link to abstract – $ for full-text)
Commentary on Twitter
Patients with time-weighted average prednisone dose greater than 20 mg/day would be classified as the high risk for HBV reactivation or hepatitis flare. Prophylactic Anti-HBV therapy may be needed for these high-risk patientshttps://t.co/qLuirdyXDK pic.twitter.com/yDJ4c072qm
— ARD & RMD Open (@ARD_BMJ) December 23, 2021